Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Jazz Pharmaceuticals plc before investing.

In this article, we go over a few key elements for understanding Jazz Pharmaceuticals plc’s stock price such as:

• Jazz Pharmaceuticals plc’s current stock price and volume
• Why Jazz Pharmaceuticals plc’s stock price changed recently
• Upgrades and downgrades for JAZZ from analysts
• JAZZ’s stock price momentum as measured by its relative strength

About Jazz Pharmaceuticals plc (JAZZ)

Before we jump into Jazz Pharmaceuticals plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Want to learn more about Jazz Pharmaceuticals plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Jazz Pharmaceuticals plc.

Jazz Pharmaceuticals plc’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Jazz Pharmaceuticals plc’s stock price was $252.860.

Jazz Pharmaceuticals plc is down 2.14% from its previous closing price of $258.380.

During the last market session, Jazz Pharmaceuticals plc’s stock traded between $250.710 and $259.060. Currently, there are approximately 61.90 million shares outstanding for Jazz Pharmaceuticals plc.

Jazz Pharmaceuticals plc’s price-earnings (P/E) ratio is currently at 535.7, which is high compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Jazz Pharmaceuticals plc Stock Price History

Jazz Pharmaceuticals plc’s (JAZZ) price is currently up 4.93% so far this month.

During the month of July, Jazz Pharmaceuticals plc’s stock price has reached a high of $261.300 and a low of $233.460.

Over the last year, Jazz Pharmaceuticals plc has hit prices as high as $261.295 and as low as $105.000. Year to date, Jazz Pharmaceuticals plc’s stock is up 48.74%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Jazz Pharmaceuticals plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Jazz Pharmaceuticals plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Jazz Pharmaceuticals plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Jazz Pharmaceuticals plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Jazz Pharmaceuticals plc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Jazz Pharmaceuticals plc (JAZZ) by visiting AAII Stock Evaluator.

Relative Price Strength of Jazz Pharmaceuticals plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Jazz Pharmaceuticals plc has a weighted four-quarter relative price strength of 17.66%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Jazz Pharmaceuticals plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Jazz Pharmaceuticals plc Stock Price: Bottom Line

As of July 31, 2026, Jazz Pharmaceuticals plc’s stock price is $252.860, which is down 2.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Jazz Pharmaceuticals plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.